Heart failure with improved ejection fraction, or HFimpEF, represents one of the most encouraging developments in cardiology over the past decade. Formally recognized in the updated universal definition of heart failure, HFimpEF describes patients whose hearts were severely weakened but whose pumping function has meaningfully recovered, often thanks to modern drug combinations, device therapies, and a deeper understanding of when and how the heart can repair itself. The breakthroughs are real, spanning pharmacology, imaging, and even early-stage gene therapy, but they come with a critical caveat that shapes every treatment decision after recovery occurs.
How HFimpEF Is Defined
For years, heart failure was classified by a single snapshot of the left ventricular ejection fraction (LVEF), the percentage of blood the heart pumps out with each beat. A healthy heart ejects roughly 50 to 70 percent; heart failure with reduced ejection fraction (HFrEF) means the number has dropped to 40 percent or below. The problem with a one-time measurement is that it misses the trajectory. A patient whose EF was 25 percent two years ago and is now 45 percent is in a fundamentally different situation than someone who has always hovered around 45 percent.
A clinical consensus statement from the Heart Failure Association of the ESC, the Heart Failure Society of America, and the Japanese Heart Failure Society addressed this by formalizing HFimpEF as a distinct category. To qualify, a patient must have a baseline LVEF of 40 percent or below, followed by at least a 10-point increase from that initial reading and a second measurement above 40 percent.1Oxford Academic (European Journal of Heart Failure). The Use of Left ventricular Ejection Fraction in the Diagnosis and Management of Heart Failure The label matters because it signals that the heart has responded to therapy, but it does not mean the disease is gone.
What Happens Inside the Heart During Recovery
When heart failure progresses, the heart undergoes “remodeling,” a cascade of changes where the chambers enlarge, the walls thicken unevenly, and the muscle itself becomes stiffer and less efficient. Recovery involves reversing this process. At the cellular level, reverse remodeling involves cardiomyocytes (heart muscle cells) shrinking back toward normal size, mitochondria regaining their ability to produce energy efficiently, and the restoration of calcium signaling that drives each heartbeat’s contraction and relaxation.2PubMed Central. Reverse Remodelling, Myocardial Recovery and Remission in Heart Failure with Reduced Ejection Fraction: Clinical Implications and Management Strategies
Think of it as the cellular machinery getting back in sync. When heart failure disrupts the cell’s internal calcium handling, the muscle fibers can’t contract properly. Recovery restores that coupling between electrical signals and physical contraction. At the same time, oxidative stress drops, the internal scaffolding of the cells reorganizes, and gene expression patterns shift away from the pathological state. This is not just the heart “trying harder.” It is structural and biochemical rebuilding.
The tissue between cells matters too. Fibrosis, the accumulation of scar-like collagen in the heart wall, is one of the stubborn obstacles to full recovery. Research using cardiac MRI has shown that changes in the extracellular volume fraction (a proxy for how much fibrosis is present) correlate with changes in exercise capacity and patient-reported quality of life, though the relationships are modest.3PubMed Central. Impact of Myocardial Fibrosis on Cardiovascular Structure, Function and Functional Status in Heart Failure with Preserved Ejection Fraction The degree of fibrosis is one reason some patients achieve dramatic recovery while others plateau.
Who Is Most Likely to Improve
The underlying cause of heart failure strongly influences the odds of EF recovery. Nonischemic cardiomyopathies, those not caused by blocked coronary arteries, are generally more responsive. In patients supported with left ventricular assist devices (LVADs) for at least six months, about 21 percent of those with nonischemic cardiomyopathy achieved an LVEF of 40 percent or above, compared with just 5 percent of those whose heart failure was caused by ischemic heart disease.4PubMed. Impact of Ischemic Heart Failure Etiology on Cardiac Recovery During Mechanical Unloading The difference makes intuitive sense: ischemic heart failure involves dead tissue from heart attacks, and scar tissue doesn’t regenerate. Nonischemic causes, such as viral myocarditis, alcohol-related damage, or tachycardia-induced cardiomyopathy, damage the muscle in ways that are sometimes fully reversible once the offending trigger is removed or controlled.
Among patients who do achieve HFimpEF, certain factors predict whether the improvement will last. Diabetes and ischemic etiology are both associated with a higher risk of the EF sliding back down. A wider QRS interval on the electrocardiogram, the presence of left bundle branch block, older age, and a larger left ventricular cavity are also independent predictors of relapse.5Egyptian Journal of Medical Human Genetics. A contemporary review on heart failure with improved ejection fraction In short, younger patients with nonischemic causes, smaller hearts, and fewer comorbidities tend to see the most durable recovery.
Peripartum cardiomyopathy, a form of heart failure that develops during or shortly after pregnancy, is a well-known example of a potentially reversible cause. Outcomes are highly variable: some women recover fully, while others progress to needing mechanical support or transplantation. The unpredictability makes close follow-up essential, but the possibility of complete recovery sets it apart from many other causes.
The Drug Therapies Driving Improvement
The modern four-pillar drug regimen for HFrEF, consisting of a renin-angiotensin system inhibitor (or its newer replacement, sacubitril/valsartan), a beta-blocker, a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor, is the primary engine behind EF improvement for most patients. The evidence for reverse remodeling with these agents has become increasingly specific.
Sacubitril/Valsartan
Sacubitril/valsartan, which combines a neprilysin inhibitor with an angiotensin receptor blocker, has shown consistent reverse remodeling effects. In one study, patients on the drug saw an average 5-point increase in ejection fraction over a median of three months of treatment, rising from about 25 percent to about 30 percent. The chambers also shrank measurably, with reductions in both the end-systolic and end-diastolic diameters and a drop in left ventricular mass.6PubMed Central. Ejection fraction improvement and reverse remodeling achieved with Sacubitril/Valsartan in heart failure with reduced ejection fraction patients A separate study confirmed these findings and added an important nuance: the remodeling effect was dose-dependent, with higher doses of the drug producing greater gains in EF and larger reductions in chamber volume.7PubMed. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction This is one reason clinicians push to titrate patients to the maximum tolerated dose.
SGLT2 Inhibitors
The SGLT2 inhibitor class, originally developed for diabetes, has turned out to be one of the most significant additions to heart failure therapy in years. Their cardiac benefits go well beyond glucose control. Randomized trial data showed that even short-term use of empagliflozin reduced left ventricular mass index in patients with type 2 diabetes and coronary artery disease, suggesting that these drugs can promote reverse remodeling within months.8PubMed Central. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review
The mechanisms are varied and still being worked out. In animal models, SGLT2 inhibitors increase the bioavailability of nitric oxide and restore the phosphorylation of titin, a giant protein that acts like a spring inside heart muscle cells and determines how stiff or compliant they are. In isolated human and mouse heart tissue, these drugs reduced passive myofilament stiffness, which directly translates to better filling during the relaxation phase. Beyond direct muscle effects, SGLT2 inhibitors also suppress fibrosis by reducing macrophage infiltration and inhibiting fibroblast differentiation.9European Heart Journal. Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction The combination of less stiffness, less fibrosis, and reduced inflammation makes them valuable for both the reduced and preserved ejection fraction ends of the heart failure spectrum.
Why Stopping Medication Is Risky
Here is the uncomfortable reality of HFimpEF: an improved ejection fraction does not mean a cured heart. The question of whether patients can safely taper or stop their medications after recovery has been tested directly, and the results are sobering.
The TRED-HF trial enrolled patients with dilated cardiomyopathy who had achieved complete recovery, with normal heart size, normal EF, and normal biomarkers. Half were randomized to gradually withdraw their medications. Within six months, 44 percent of those who stopped treatment relapsed, compared with none in the group that continued therapy. When the continuation group later attempted withdrawal themselves, 36 percent relapsed within the next six months.10The Lancet. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial Even in the best-case scenario, with patients selected for full recovery, roughly four in ten lost their gains after stopping drugs.
A larger observational study reinforced this message with specific drug classes. Withdrawal of renin-angiotensin system inhibitors or sacubitril/valsartan was independently associated with a 38 percent higher risk of cardiovascular death or heart failure hospitalization. Stopping mineralocorticoid receptor antagonists carried a 36 percent increase. Interestingly, stopping beta-blockers did not show a statistically significant increase in risk in that analysis, though this should not be taken as a green light to discontinue them.11PubMed. Withdrawal of Guideline-Directed Medical Therapy in Patients With Heart Failure and Improved Ejection Fraction Current guidelines accordingly recommend sustained, indefinite guideline-directed medical therapy for all patients with HFimpEF.12PubMed. Management of Heart Failure With Improved Ejection Fraction: Current Evidence and Controversies
European expert consensus echoes this, stressing the necessity of continued therapy and individualized monitoring to minimize the risk of relapse. While a subset of patients achieves sustained recovery, others remain susceptible to deterioration, and there is currently no reliable way to tell the two groups apart in advance.13European Journal of Heart Failure. Heart Failure Improvement, Remission, and Recovery: A European Journal of Heart Failure Expert Consensus Document
The Prognosis Advantage
Despite the ongoing disease risk, achieving HFimpEF translates to a substantially better prognosis. A meta-analysis found that patients with HFimpEF had roughly half the mortality risk compared with those who remained in HFrEF, and about 60 percent lower risk of cardiac hospitalization. Perhaps surprisingly, HFimpEF patients also had better outcomes than patients with heart failure with preserved ejection fraction (HFpEF), with lower mortality and fewer hospitalizations.14PubMed Central. Prevalence and Prognosis of HFimpEF Developed From Patients With Heart Failure With Reduced Ejection Fraction: Systematic Review and Meta-Analysis That last point surprises some clinicians, since HFpEF is sometimes perceived as the “milder” form. But it reflects the fact that HFpEF is its own complex disease with limited effective treatments, while HFimpEF patients are typically on a well-optimized drug regimen that actively protects the heart.
Tracking Recovery With Biomarkers and Imaging
Knowing whether the heart is genuinely remodeling in the right direction requires more than periodic echocardiograms. Blood biomarkers offer a window into what’s happening at the tissue level. In the EVALUATE-HF trial, patients treated with sacubitril/valsartan showed a 31 percent median decrease in NT-proBNP over 24 weeks, and that drop correlated with reductions in cardiac volumes and improvements in both systolic and diastolic function. A different biomarker, cardiac troponin T, declined by about 3 percent and tracked with reductions in left ventricular mass but not with functional improvement. A third marker, soluble ST2, correlated with improvements in how patients felt, but not with structural changes on imaging.15European Journal of Heart Failure. Changes in Cardiac Biomarkers in Association with Alterations in Cardiac Structure and Function, and Health Status in Heart Failure with Reduced Ejection Fraction: The EVALUATE-HF Trial Each biomarker reflects a different dimension of recovery, and none alone tells the whole story.
On the imaging side, advanced echocardiographic techniques like speckle-tracking strain analysis are proving more informative than EF alone. In hospitalized patients with nonischemic cardiomyopathy, baseline longitudinal strain predicted who would go on to recover their EF, and a predictive model combining strain with clinical variables achieved high accuracy. Patients who recovered had smaller baseline chamber sizes and better preserved strain mechanics at the time of diagnosis.16PubMed Central. Baseline Longitudinal Strain Predicts Recovery of Left Ventricular Ejection Fraction in Hospitalized Patients With Nonischemic Cardiomyopathy Cardiac MRI adds further detail. In a multicenter study of patients with dilated cardiomyopathy, left ventricular global longitudinal strain measured by MRI was the only strain parameter that remained a significant independent predictor of outcomes in multivariable analysis, outperforming EF and even the presence of late gadolinium enhancement (a marker of scar).17PubMed. Prognostic Utility of Cardiac MRI Myocardial Strain Parameters in Patients With Ischemic and Nonischemic Dilated Cardiomyopathy: A Multicenter Study
Artificial Intelligence for Predicting Who Will Recover
One of the most active frontiers is using machine learning to identify which patients will respond to treatment before waiting months to find out. Several research groups have applied supervised machine learning to cardiac imaging and electronic health records with impressive early results. In one study, an ML model trained on cardiac MRI data from patients with idiopathic dilated cardiomyopathy was able to distinguish responders from nonresponders with an area under the curve (AUC) of 0.94, relying heavily on regional strain measurements. A separate team predicted lack of EF recovery at one year after sacubitril/valsartan treatment with an AUC of 0.86, finding that shorter heart failure duration and less extensive remodeling at baseline were the strongest predictors.18PubMed Central. Role of Artificial Intelligence and Machine Learning to Create Predictors, Enhance Molecular Understanding, and Implement Purposeful Programs for Myocardial Recovery
A multi-site study using electronic health records tested various ML models for predicting EF changes over one year. The XGBoost algorithm performed best, achieving AUCs between 0.83 and 0.90 across three independent hospital systems for predicting a 30 percent increase in EF. Predicting EF decreases was substantially harder, with AUCs ranging from 0.54 to 0.68 for the same model. Baseline EF, age, sex, and the type of heart disease were the most influential features.19Scientific Reports. Prediction of left ventricular ejection fraction changes in heart failure patients using machine learning and electronic health records: a multi-site study These tools are not yet used in routine clinical decision-making, but they suggest a future where treatment can be personalized based on a patient’s predicted likelihood of recovery.
Device Decisions After Improvement
Many patients with HFrEF receive an implantable cardioverter-defibrillator (ICD) to protect against sudden cardiac death. When the EF subsequently improves, a thorny question arises: should the device be replaced when its battery runs out, or can it be safely removed? The risk of dangerous arrhythmias drops with EF improvement, but it does not vanish. A study of ICD patients who achieved HFimpEF found that while the risk of appropriate device therapies (shocks delivered for genuinely life-threatening rhythms) was reduced, it was not eliminated.20PubMed. Risk of Appropriate Implantable Cardioverter-Defibrillator Therapies and Sudden Cardiac Death in Patients With Heart Failure With Improved Left Ventricular Ejection Fraction Current practice favors shared decision-making, weighing the patient’s residual arrhythmia risk against the procedural risks of generator replacement, which include infection and lead complications. There is no one-size-fits-all answer.
Emerging Therapies on the Horizon
Beyond the established drug pillars, several newer approaches are generating cautious optimism. Cardiac contractility modulation (CCM), a device therapy that delivers timed electrical signals to the heart muscle during the contraction phase (distinct from pacing or defibrillation), has shown measurable benefits. A meta-analysis of clinical trials found that after 24 months, CCM was associated with a roughly 4-point improvement in ejection fraction and significant improvements in exercise capacity and quality-of-life scores compared with controls.21Cardiovascular Therapy and Prevention. Cardiac contractility modulation in patients with heart failure with reduced ejection fraction: a meta-analysis of Russian clinical trials
Gene therapy for heart failure, while still largely in preclinical and early clinical stages, is targeting the molecular machinery that breaks down in the failing heart. Key strategies include restoring calcium ion regulation (the same intracellular process that reverse remodeling corrects), promoting therapeutic angiogenesis (new blood vessel growth), and activating regenerative pathways.22PubMed Central. Gene Therapy for Heart Failure Progress in CRISPR-based genome editing and improved viral vector delivery systems has strengthened the feasibility of targeting these pathways. In parallel, stem-cell-derived cardiomyocytes show regenerative potential, though challenges related to immune rejection, cell survival, and scalability remain substantial.23Egyptian Journal of Medical Human Genetics. Emerging advances in gene and cell therapy for heart failure: a systematic review
Exercise Rehabilitation as a Contributor
Exercise training is not just a feel-good add-on for patients with heart failure. Tailored programs combining aerobic and resistance exercise have been shown to improve peak oxygen consumption, six-minute walking distance, and quality of life through adaptations that span multiple organ systems, from enhanced cardiac output reserve to skeletal muscle metabolic remodeling and reduced systemic inflammation.24PubMed Central. Advances in pathophysiological mechanisms and therapeutic efficacy of exercise rehabilitation in patients with heart failure with preserved ejection fraction For HFimpEF patients, exercise rehabilitation serves a dual role: it supports the physiological changes that sustain recovery, and it provides functional improvements that drugs alone may not deliver. The benefit appears to come from addressing the peripheral consequences of heart failure, such as deconditioning and skeletal muscle wasting, as much as from direct cardiac effects.
Most cardiac rehabilitation programs for heart failure patients build gradually, starting with supervised moderate-intensity aerobic sessions and progressing over weeks. The evidence is strongest for structured programs rather than generic advice to “stay active,” and adherence matters enormously. Patients who drop out early or exercise inconsistently see much smaller gains, which is one reason many programs now incorporate remote monitoring and patient education to keep engagement high.